Company: CRL
Filing Date: 2025-02-19
Form Type: 10-K
Source: 0001100682-25-000011
Chunk: 83

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-02-19
Form: 10-K
Item: Item 15
Chunk 83
---
Item 15.    Exhibits and Financial Statement Schedules

Item 15(a)(1) and (2) Financial Statements and Schedules

See "Index to Consolidated Financial Statements and Financial Statements Schedules" at Item 8 to this Annual Report on Form 10-K. Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto.

Item 15(a)(3) and Item 15(b) Exhibits

We have identified below each management contract and compensation plan filed as an exhibit to this Annual Report on Form 10-K.

Exhibit No.DescriptionFiled with this Form 10-KIncorporation by ReferenceFormFiling DateExhibit No.3.1Second Amended and Restated Certificate of Incorporation of Charles River Laboratories International, Inc. dated June 5, 2000S-1/AJune 23, 20003.13.2Sixth Amended and Restated By-Laws of Charles River Laboratories International, Inc. 8-KDecember 15, 20213.14.1Form of Common Stock certificate, $0.01 par value, of Charles River Laboratories International, Inc.S-1/AJune 23, 20004.14.2Description of Securities10-KFebruary 11, 20204.24.3Charles River Laboratories International, Inc. Form of Performance Share Unit granted under the 2018 Incentive Plan10-QAugust 5, 202010.34.4Charles River Laboratories International, Inc. Indenture Agreement with MUFG Union Bank, N.A. as Trustee dated April 3, 20188-KApril 3, 20184.14.5Charles River Laboratories International, Inc. Second Supplemental Indenture, dates as of October 23, 2019, to the Indenture dated as of April 3, 20188-KOctober 23, 20194.14.6Form of Note for 4.250% Senior Notes due 20288-KOctober 23, 20194.24.7Indenture, dated as of March 23, 2021, between Charles River International, Inc. and U.S. Bank National Association, as trustee8-KMarch 23, 20214.14.8First Supplemental Indenture, dated as of March 23, 2021, by and among the Charles River Laboratories International, Inc., the Guar